All In MedTech

Device Trial Radar · NCT07363161

BASel Kosten-Effektivitäts-Trial: Drug-coated BALLoon (DCB) vs. Drug-eluting Stent (DES) Strategy in High-risk Patients With Coronary Artery Disease (CAD)

BASKET BALL - a Prospective, Multicenter, International, Open-label, Randomized Clinical Trial Comparing the Sirolimus-DCB Strategy vs. DES Strategy in de Novo High-risk Patients

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,184 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,184

Planned (sponsor's estimate)

Start

Jun 17, 2026

Primary completion

Jun 2027

Study completion Mar 2031

Sponsor

Lead sponsor
B. Braun Melsungen AGNot on our public-company list
Sponsor type
Industry
First posted
Jan 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this randomized, multicenter, international, open-label clinical trial is to demonstrate that, in the context of percutaneous coronary intervention for complex coronary artery disease, a SeQuent® SCB interventional strategy is non-inferior to a new-generation DES strategy in terms of a 12- and 36-month composite of Target Vessel Failure (TVF), that includes: * cardiovascular death (CV death), * target vessel related MI (TV-MI), * clinically indicated target vessel revascularization (ci-TVR), * bleeding according to Bleeding Academic Research Consortium (BARC) Types 3-5. Eligible subjects will be assigned in a 1:1 ratio to receive treatment of all lesions with either the SeQuent® SCB-based strategy or a DES-based strategy. The randomization will be performed prior to the index procedure once signed informed consent has been obtained and all eligibility criteria have been confirmed. All Subjects will be followed for clinical outcomes at 3 months, 1, 2, and 3 years. A subset of 138 randomized patients will undergo control angiography after one-year clinical follow-up (+1 month). An independent core laboratory will analyze all baseline angiograms. If, at 36 months, the non-inferiority of the SeQuent® SCB strategy compared to the DES strategy is achieved, superiority in terms of TVF and BARC Type 3-5 bleeding will be tested. An optional extension of follow-up to 6 years may be implemented based on interim results and the joint decision of the Steering Committee and the Sponsor. Details regarding this optional extension are provided in the Clinical Investigation Plan.

Conditions

  • Coronary Artery Disease (CAD)

Interventions

  • PCIDevice

    PCI with SeQuent® SCB

  • PCIDevice

    PCI with DES

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Target Vessel Failure (TVF) and bleeding according to Bleeding Academic Research Consortium (BARC) Types 3-5Time frame: at 12 months (after intervention)

1 more outcomes with a free account

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Universität des Saarlandes - Klinik für Innere Medizin III

    Homburg, Germany · Not yet recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.